Recent Updates
Recently added Catalysts
OCGN Positive Sentiment Score: 70/100

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Key Takeaway: Ocugen, Inc. will host a conference call on May 5, 2026, at 8:30 a.m. ET to discuss its first quarter financial results and provide business updates. The call will include a pre-market earnings announcement and will be accessible via dial-in and webcast. A replay will be available afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ocugen is hosting a conference call to discuss business updates.
  • The company is a leader in gene therapies for blindness diseases.
  • They have a promising gene-agnostic approach to therapy.

Full Press Release Details

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers:(800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID:4973685Webcast:Available on theeventssection of the Ocugeninvestor site
A replay of the call and archived webcast will be available on the Ocugeninvestor site.
About Ocugen, Inc.Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more atwww.ocugen.comand follow us onXandLinkedIn.Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.Contact:Tiffany HamiltonAVP, Head of CommunicationsTiffany.Hamilton@ocugen.com

Frequently Asked Questions

When is Ocugen's conference call scheduled?

The conference call is scheduled for May 5, 2026, at 8:30 a.m. ET.

How can I participate in the conference call?

Participants can join by dialing (800) 715-9871 for U.S. callers or (646) 307-1963 for international callers.

What will be discussed during the call?

The call will cover Ocugen's Q1 2026 financial results and provide business updates.

Will there be a replay of the conference call?

Yes, a replay of the call will be available on the Ocugen investor site.

Last updated: Apr 29, 2026